Faricimab for high-frequent Aflibercept treated Neovascular age-related macular degeneration: a monocenter, randomized, double-masked comparator-controlled study (FAN study)
This study is looking into 'wet' age-related macular degeneration (AMD), a common cause of sight loss. It compares two existing medicines, Vabysmo and Eylea, which are given as injections into the eye. The main goal is to find out if one treatment can help keep the retina (the light-sensing part of the eye) dry and stable for a longer time between injections. This would mean fewer trips to the hospital for treatment. Researchers will also check how well people's vision is maintained and how many injections are needed over one year. The study helps doctors make the best decisions for people living with 'wet' AMD.
At a glance
What is this study about?
This study is for people who have a serious eye condition called 'wet' age-related macular degeneration (AMD). In 'wet' AMD, abnormal blood vessels grow at the back of the eye and leak fluid, which can damage your central vision. This can make everyday tasks like reading or recognising faces very difficult. Current treatments involve regular injections into the eye to stop the leaking, but these often need to be given frequently.
The purpose of this particular study is to compare two medicines currently used for 'wet' AMD: Vabysmo and Eylea. Both medicines work by targeting the substances that cause these abnormal blood vessels to grow and leak. Researchers want to see if one of these treatments is better at keeping the fluid away from the back of the eye for longer periods of time. This is important because if the fluid stays away, it might mean people need fewer injections overall.
By comparing Vabysmo and Eylea, doctors hope to learn which treatment allows for longer gaps between injections, while still keeping the eye healthy and vision stable. This could significantly improve the quality of life for people with 'wet' AMD, as it would mean fewer hospital visits and less discomfort from frequent injections. The study will look closely at how long the eye stays dry, how vision changes, and the total number of injections needed.
Key takeaways
- Compares two existing eye treatments (Vabysmo and Eylea) for 'wet' AMD.
- Aims to find out if one treatment allows for longer periods between injections.
- Could reduce the number of hospital visits for people with 'wet' AMD.
- Checks how well vision is maintained over one year.
- Participants will be randomly assigned to one of the two treatments.
Who may be eligible?
To join this study, participants must be at least 18 years old. Both men and women can take part. The study is specifically for people who have been diagnosed with 'wet' age-related macular degeneration (AMD).
Participants also need to have been treated with a medicine called Aflibercept (which is the main ingredient in Eylea) fairly often in the past for their AMD. This means the study is looking at people who might need very regular injections to control their condition.
The specific details about how many previous injections and other health conditions will be carefully checked by the study doctor to make sure it's safe and appropriate for someone to join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with 'wet' age-related macular degeneration (AMD)?
- Have you received regular Aflibercept injections for your AMD in the past?
- Are you willing to have regular eye injections and clinic visits for about a year?
What does participation involve?
If you decide to take part in this study, you will be randomly assigned to receive either Vabysmo or Eylea injections into your affected eye. This means you won't get to choose which medicine you receive, and neither you nor your study doctor will know which one it is (this is called 'double-masked'). You will have regular visits to the clinic for eye examinations, vision tests, and the injections. Initially, the injections might be quite frequent, but the aim of the study is to see if the time between injections can be extended. Your eye will be checked regularly for fluid. The 'success' of the treatment is measured by seeing how long your eye remains free of fluid between injections. The total study duration will be about one year (56 weeks) with regular follow-up appointments.
Potential risks and benefits
Locations (1)
- —UnverifiedAustria
Common questions
What is 'wet' age-related macular degeneration (AMD)?
It's an eye condition where unwanted blood vessels grow and leak fluid at the back of your eye, affecting your central vision.
What are Vabysmo and Eylea?
They are medicines given as injections into the eye to stop the leaking blood vessels caused by 'wet' AMD.
Will I know which treatment I'm getting?
No, this is a 'double-masked' study, meaning neither you nor your doctor will know if you're getting Vabysmo or Eylea until after the study ends.
How long will the study last?
The study will last about one year, during which you'll have regular clinic visits for treatments and check-ups.
What is the main goal of the study?
The main goal is to see which treatment can keep your eye free of fluid for longer periods, potentially meaning fewer injections.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.